arrow_back Back to App

Increased Support for Biosimilar Medicines in Medicare

This act aims to increase the availability of more affordable biosimilar medicines for individuals covered by Medicare. These changes could provide patients with easier access to drugs that are often cheaper alternatives to more expensive biological products, potentially reducing their healthcare costs. Increased payments to manufacturers are intended to encourage the development and market entry of more such medicines.
Key points
Temporary payment increase for certain biosimilar biological products under Medicare Part B for 5 years.
Aims to encourage the development and use of more affordable biosimilar medicines.
Could lead to lower out-of-pocket costs for Medicare patients.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_2815
Sponsor: Rep. Schrader, Kurt [D-OR-5]
Process start date: 2021-04-22
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

BIOSIM Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_2815.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-04-22.

What are the main provisions?

Key points include:

  • Temporary payment increase for certain biosimilar biological products under Medicare Part B for 5 years.
  • Aims to encourage the development and use of more affordable biosimilar medicines.
  • Could lead to lower out-of-pocket costs for Medicare patients.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Schrader, Kurt [D-OR-5].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

CATEGORIES

Health